In this work, we showed that the targeted toxin DARPin-LoPE composed of HER2-specific DARPin and low immunogenic exotoxin A fragment effectively inhibits the growth of HER2-expressing human ovarian carcinoma xenografts, while showing significantly less toxicity and immunogenicity than its previous version DARPin-PE40. The gene discussed is ERBB2; the disease is ovarian carcinoma.